This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-Learn About Coagulation Disorders
-What are Bleeding Disorders?
 History of Bleeding Disorders
 Types of Bleeding Disorders
 Types of Bleeds
 Bleeding Disorders and Women
 Caring for the Newly Diagnosed Child
 Psychosocial Issues
-Complications, including Inhibitors
 For Consumers
-For Providers
 The Challenge of Inhibitors
-Why Some Patients Develop Inhibitors
 Measuring Inhibitors
 Prognosis for Inhibitor Patients
 Social and Emotional Concerns
 Discussion Group
 Future Therapies
 What are Clotting Disorders?
 Comprehensive Medical Care - Hemophilia Treatment Centers
 Medical and Scientific Advisory Council
 Financial and Insurance Issues
 HANDI, NHF's Information Resource Center
 Web Links



Why Some Patients Develop Inhibitors

Individuals with a severe factor deficiency (FVIII or FIX levels at <0.01 U/mL) have the highest risk of developing inhibitors. Risk factors for inhibitor development include race, with blacks and Hispanics having increased risk; severity of hemophilia, severe being at highest risk; genetic defect, with defects such as large deletions being higher; and family history of inhibitor also increasing the risk. Other factors such as presence of inflammatory states, age at first infusion, intervals between exposures etc., have been suggested but remain unproven.

The immunologic mechanisms regulating inhibitor development are not fully known, but it is clear that certain patients may have traits that put them at higher risk for developing one inhibitor more than another.

There is some evidence that histocompatibility class II gene products, the type of mutation causing the hemophilia, as well as defective functioning of some immunosuppressor mechanisms, can all contribute to the development of inhibitors.



This section of our Web site is sponsored by: